Accretion Pharmaceuticals (NSE:ACCPL) Total Equity: ₹547.1 Mil (As of Mar. 2026)


NSE:ACCPL Accretion Pharmaceuticals Ltd NSE:ACCPL
18 GF Score
Price ₹155.65
! 6 Warning Signs
View Full Analysis

What is Accretion Pharmaceuticals Total Equity?

Accretion Pharmaceuticals NSE:ACCPL -3.92% 18 Total Equity is ₹547.1 Mil as of Mar. 2026. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 6 warning signs investors should review.

Accretion Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was ₹547.1 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Accretion Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Accretion Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accretion Pharmaceuticals Total Equity Chart

Accretion Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
30.76 38.43 53.48 0.00 547.09

Accretion Pharmaceuticals Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Equity Get a 7-Day Free Trial 53.48 0.00 0.00 465.79 547.09
NSE:ACCPL
18GF Score
Accretion Pharmaceuticals Ltd NSE:ACCPL
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accretion Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Accretion Pharmaceuticals's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=766.555-219.47
=547.1

Accretion Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=766.555-219.47
=547.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹547.1 Mil mean?
Accretion Pharmaceuticals (NSE:ACCPL) has a Total Equity of ₹547.1 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Accretion Pharmaceuticals and its competitors.
Is Accretion Pharmaceuticals' Total Equity too high?
Accretion Pharmaceuticals' current Total Equity is ₹547.1 Mil. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Total Equity compare to LLY and JNJ?
Accretion Pharmaceuticals' Total Equity of ₹547.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Accretion Pharmaceuticals and its competitors. Accretion Pharmaceuticals's current Total Equity is ₹547.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Total Equity of ₹547.1 Mil. The current Total Equity is ₹547.1 Mil. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Total Equity is ₹547.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accretion Pharmaceuticals Business Description

Address 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna-Chacharwadi, Ta - Sanand District, Ahmedabad, GJ, IND, 382213
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score

Get the complete analysis for NSE:ACCPL

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹155.65
Price